Ads
related to: pembrolizumab clinical trials- Paying for KEYTRUDA
Find Assistance and Payment
Information for Eligible Patients.
- How Does KEYTRUDA Work?
Learn About KEYTRUDA and How
It May Help Eligible Patients.
- Clinical Trial Results
Get Information About Clinical
Trial Results for KEYTRUDA.
- Taking KEYTRUDA
Learn More About Treatment
With KEYTRUDA Here.
- Learn About KEYTRUDA
Learn About KEYTRUDA and How
It May Help Eligible Patients.
- Resources and FAQ
Find Patient Information, FAQs,
and Additional Resources Here.
- Paying for KEYTRUDA
Search results
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
WPRI Providence· 53 minutes agoThe volume of data being presented by Astellas reinforces its commitment to changing the course of cancer treatment through targeted therapies for hard...
Pipeline Moves: Phase III completion for Corcept’s relaorilant
Clinical Trials Arena via Yahoo Finance· 5 hours agoThe Phase I trial’s (NCT05152212) status was updated from active, not recruiting to completed on...
Calliditas announces positive topline results of phase 2 head and neck cancer trial
BioPharma-Reporter· 4 days agoThe analysis showed statistically significant improvements in progression-free survival (PFS), as...
Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting
Digital Journal· 2 hours agoASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of ...
Revolution Medicines Inc (RVMD) (Q1 2024) Earnings Call Transcri
Guru Focus· 5 days agoThe company expects to share updated clinical data from ongoing studies in the second half of the year, which could potentially transform the company's prospects and provide ...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
WKBN 27 Youngstown· 6 days ago...Phase 2 dose for IDE397 in MTAP squamous NSCLC, based on clinical efficacy observed in this indication, including multiple PRs by RECIST 1.1...publication strategy in 2024First-patient-in (FPI) for Phase 1 trial of IDE397 in combination with Gilead's Trodelvy® in ...IDE161 in combination with...
Fundamental Research Paved the Way for the Development of Vorasidenib
National Cancer Institute· 2 days agoDuring the 2023 American Society of Clinical Oncology (ASCO) annual meeting, a plenary presentation...
Billionaire-Backed Cancer Researcher Claire Mazumdar Finds Entrepreneurial Niche
Forbes· 3 days agoAs the niece of biotech billionaire Kiran Mazumdar-Shaw—the founder of listed biopharma firm Biocon...
BioNTech shares hold rating, price target raised By Investing.com
Investing.com· 6 days agoThe adjustment comes after the company reported first-quarter sales of their COVID-19 vaccine,...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 4 days agoCarisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights PR Newswire PHILADELPHIA, May 9, 2024 Announced CT-0525 as lead product candidate for anti-HER2 program; initial data expected by year-end 2024 Presented
Ads
related to: pembrolizumab clinical trials